PDF(Pubmed)
Abstract：
CAR-T cell therapy, a novel therapeutic approach that has attracted much attention in the field of cancer treatment at present, has become the subject of many studies and has shown great potential in the treatment of hematological malignancies, such as leukemia and lymphoma. This study aims to analyze the characteristics of articles published on CAR-T cell therapy in the lymphoma field and explore the existing hotspots and frontiers. The relevant articles published from 2013 to 2022 were retrieved from the Web of Science Core Collection. CiteSpace, VOSviewer, Bibliometric online analysis platform, Microsoft Excel, and R software were used for bibliometric analysis and visualization. The number of publications related to the research has been increasing year by year, including 1023 articles and 760 reviews from 62 countries and regions, 2092 institutions, 1040 journals, and 8727 authors. The United States, China, and Germany are the main publishing countries in this research field. The top 10 institutions are all from the United States, the journal with the highest impact factor is BLOOD, the author with the most publications is Frederick L Locke, and the most influential author is Carl H June. The top three keywords are \"Lymphoma,\" \"Immunotherapy,\" and \"Therapy.\" \"Maude (2014)\" is the most cited and strongest burstiness reference over the past decade. This study provides a comprehensive bibliometric analysis of CAR-T cell therapy in lymphoma, which can help researchers understand the current research hotspots in this field, explore potential research directions, and identify future development trends.
摘要：
CAR-T细胞疗法,一种新颖的治疗方法，目前在癌症治疗领域备受关注，已成为许多研究的主题，并在血液恶性肿瘤的治疗中显示出巨大的潜力，如白血病和淋巴瘤。本研究旨在分析淋巴瘤领域发表的CAR-T细胞治疗相关文章的特点,探讨现有的热点和前沿。2013年至2022年发表的相关文章来自WebofScience核心合集。CiteSpace,VOSviewer,文献计量在线分析平台，MicrosoftExcel,使用R软件进行文献计量分析和可视化。与这项研究有关的出版物数量逐年增加,包括来自62个国家和地区的1023篇文章和760篇评论，2092个机构，1040日记帐，8727位作者美国,中国,德国是这一研究领域的主要出版国。排名前10位的机构都来自美国,影响因子最高的期刊是血液，出版物最多的作者是弗雷德里克·L·洛克，最有影响力的作家是卡尔·H·琼。前三个关键词是\"淋巴瘤,\"\"免疫疗法,\"和\"治疗。\“\”Maude（2014）\”是过去十年中引用最多和最强的突发性参考。这项研究提供了对淋巴瘤中CAR-T细胞疗法的全面文献计量分析，这可以帮助研究人员了解该领域当前的研究热点，探索潜在的研究方向，并确定未来的发展趋势。
